Articles tagged with Chemotherapy
Researchers found that cancer stem cells regrow and respond to chemotherapy-induced damage by releasing prostaglandin E2, leading to therapy resistance. Blocking PGE2 could potentially enhance therapeutic response, offering a promising new treatment for bladder cancer.
Researchers at UNC School of Medicine found that the chemotherapy drug topotecan suppresses a gene essential for normal brain function, leading to neurological side effects like memory loss and confusion. The effects are reversible upon removal of the drug, suggesting a potential link to autism.
Breast cancer patients undergoing chemotherapy and immediate breast reconstruction are at risk of thrombotic complications, which can delay or modify reconstructive plans. In some cases, these complications require anticoagulation therapy and may necessitate additional surgeries.
Researchers at the University of Adelaide have discovered that cancer cells with chromosomal instability are vulnerable to mild metabolic disruption, making them a potential target for new therapy. The study's findings suggest that targeting these unstable cells could lead to more effective treatments with fewer side effects.
Scientists from Queen Mary University of London have developed a new therapy for advanced bladder cancer, showing significant tumor shrinkage in patients. The treatment, MPDL3280A, has been given breakthrough therapy designation status by the US FDA and has promising results in a phase one clinical trial.
A £600,000 grant from Cancer Research UK will fund a research study investigating the efficacy of BTK inhibiting drugs in treating mantle cell lymphoma. The trial will compare these new drugs to standard chemotherapy and aim to improve life expectancy and quality of life for patients.
Researchers at University of Cincinnati have found a Food and Drug Administration-approved therapy effective in treating older and African American patients with non-small cell lung cancer. The study suggests that gefitinib improves quality of life and outcomes for this subgroup of patients, who often face limited treatment options.
A novel combination therapy using low-dose chemotherapy with an antiangiogenic treatment, 3TSR, improved survival rates in an animal model of ovarian cancer. The treatment resulted in tumor regression, improved blood flow, and more efficient delivery of chemotherapy drugs with reduced side effects.
Researchers have developed a potent and systematic AC inhibitor, tilting the balance between pro-aging/death and pro-life chemical signals in favor of death. The compound may be used as 'chemosensitizers' to enhance anti-tumoral drug efficacy.
Researchers have developed a computational model to design fusion proteins that target cancer cells while minimizing harm to healthy cells. The model predicts the behavior of these proteins and can help identify promising candidates for drug testing.
A new review reveals that anti-cancer drugs must obtain regulatory approval, change physician prescription habits and gain patient compliance before being incorporated into daily practice.
Researchers at University of Guelph found a potential breakthrough in treating late-stage ovarian cancer by shrinking tumours and improving drug delivery. This approach may lead to novel treatment options with reduced morbidity and mortality.
Researchers at Ohio State University have discovered a promising therapy combining an oncolytic virus with doxorubicin to treat advanced or recurrent ovarian cancer. The treatment showed significant antitumor activity in animal models, increasing survival and inducing programmed cell death in cancer cells.
A recent study published in the British Journal of Surgery found that extending surgical resection after two cycles of chemotherapy may be beneficial for some pediatric patients with hepatoblastoma. The research, conducted at Children's Hospital Los Angeles, suggests a potential reduction in complications from chemotherapy.
Researchers at Paxman Coolers and the University of Huddersfield are developing new scalp cooling technology to improve hair preservation rates among cancer patients. The project aims to increase hair retention from 50% to 80%, with the goal of reducing hair loss during chemotherapy.
Research at Children's Hospital Los Angeles found that obese patients with acute lymphoblastic leukemia are more than twice as likely to have minimal residual disease, a strong predictor of long-term survival and disease recurrence. The study suggests modifying chemotherapy regimens for obese patients may improve outcomes.
A new study found that nearly two-thirds of patients treated for stage 3 colorectal cancer reported some measure of financial burden due to their treatment. The burden was greatest among patients who received chemotherapy and younger patients in low-paying jobs.
Scientists at Brigham Young University have discovered two proteins that trigger autophagy in cancer cells, offering a potential therapeutic avenue for targeted treatment. The study's unique approach led to the identification of a protein pair responsible for switching on autophagy under stress conditions.
Recent trends in cancer drug spending show a significant increase, with hospitals profiting from discounted prices through the 340B program. Researchers found that hospitals serving more affluent communities increased their profits, while patients may not receive the intended discounts.
Researchers have identified a class of chemical compounds that make cancer cells more sensitive to chemotherapeutic drugs. The compounds, referred to as T8, specifically target the protein disulfide isomerase enzyme and induce programmed cell death in rapidly dividing cancer cells.
Preliminary data from a phase III trial suggest nivolumab achieves better response rates and longer response durations than standard chemotherapy in patients with unresectable metastatic melanoma. The drug has a lower toxicity profile compared to chemotherapy, promoting a sustained immune response.
The IMPRESS trial found that continued gefitinib therapy after resistance development in lung cancer did not improve progression-free survival. Chemotherapy alone remains the standard treatment for patients with EGFR mutation-positive non-small cell lung cancer.
Adding cediranib to standard chemotherapy improves tumour shrinkage and adds a modest improvement in progression-free survival for patients with relapsed or metastatic cervical cancer. The study, published in Annals of Oncology, shows greater tumour shrinkage and increased median progression-free survival compared to chemotherapy alone.
The CLEOPATRA study demonstrated a significant survival benefit of 15.7 months with the combination therapy, outperforming previous studies. The long-term safety profile and cardiac safety were also maintained.
A Korean study showed that patients with low levels of thymidylate synthase in their lung tumors experienced greater benefits from treatment with pemetrexed and cisplatin. The enzyme's expression level can also serve as a prognostic biomarker for overall survival.
A phase III trial showed that Rolapitant significantly reduced nausea and vomiting in patients receiving cisplatin-based chemotherapy. The study found that 72.7% of patients experienced complete response, with improved quality of life outcomes.
Children exposed to chemotherapy or radiotherapy in utero suffer no negative impacts on mental or cardiac development, according to international studies presented at ESMO 2014. These findings confirm that chemotherapy and radiotherapy during pregnancy do not endanger the fetus and its subsequent development.
Researchers at St. Jude Children's Research Hospital found that adjusting treatment based on early response to chemotherapy significantly boosts the survival of young patients with a poor-prognosis leukemia subtype associated with the Philadelphia chromosome-like acute lymphoblastic leukemia. The study included 344 children and adolesc...
A study from the University of Pennsylvania found that combining exercise with chemotherapy shrunk tumors more than chemotherapy alone in a mouse model of melanoma. Exercise increased blood flow to the tumor, bringing more of the drug into the bloodstream, and may help reduce side effects.
A study published in the Journal of Clinical Pathology suggests that adding a wild berry extract to chemotherapy cycles may improve treatment outcomes for pancreatic cancer. The researchers found that the extract induced cell death and boosted the effectiveness of the conventional drug gemcitabine.
A study found that combining chemotherapy and stereotactic ablative radiation (SABR) may be an effective treatment option for patients with locally advanced pancreatic cancer. After undergoing this treatment, nearly 90% of patients were able to undergo surgery, resulting in a high success rate.
A combination of chemotherapy drugs cisplatin and pemetrexed improved survival rates and response to advanced cervical cancer by 31% compared to standard alternative, while being less toxic to patients. Adding bevacizumab further increased patient survival, suggesting the cocktail may offer further benefits.
Pitt researchers identify natural TH17 cells as a key player in preventing oral thrush, a common infection among HIV patients and those with impaired immune systems. These innate immune cells produce IL-17 to fight Candida albicans, a fungus that causes painful white lesions.
A new antifungal, isavuconazole, has been shown to be as effective as an existing drug, voriconazole, in treating invasive mold disease in cancer patients. Isavuconazole had significantly fewer drug-related adverse events than voriconazole, particularly in the eye, skin, and liver.
A new blood test developed by researchers at the University of Manchester and The Christie NHS Foundation Trust may soon be used to tailor treatment for ovarian cancer patients. The test predicts patient response to targeted therapies such as bevacizumab, allowing for personalized treatment plans while sparing those unlikely to benefit.
Researchers found BIM deletion independently predicts overall and progression-free survival in advanced NSCLC patients, particularly in those treated with EGFR TKIs or chemotherapy. The study suggests considering BIM deletion as a clinical trial stratification factor for Asian NSCLC patients.
Researchers at Norwegian University of Science and Technology discovered that eliminating nerve signals sent to cancer stem cells can suppress gastric tumor growth. Botox, commonly used for beauty treatments, was found to be highly effective in treating stomach cancer.
A study in The Journal of Molecular Diagnostics found a combination of nucleic acid sequence-based amplification and real-time quantitative PCR detects aspergillosis with 100% accuracy. This diagnostic test has the potential to improve patient outcomes by providing early detection of this potentially deadly fungus.
Scientists have successfully tested a new treatment for aggressive brain cancer, using tiny gold nanoparticles to kill tumour cells. The treatment combines chemotherapy with radiotherapy, targeting cancer cells directly and enhancing the impact of conventional treatments.
Chloroquine has been shown to inhibit tumor growth and metastases by normalizing abnormal blood vessels in tumors. This results in an increased barrier function blocking cancer cell dissemination and enhanced tumor perfusion increasing the response of the tumor to chemotherapy.
A large-scale study of over 180,000 people found that patients treated with metformin for type 2 diabetes had a small but statistically significant improvement in survival compared to non-diabetics. Meanwhile, those on sulphonylureas experienced reduced survival, even without statistical manipulation.
A Kaiser Permanente study found that older adults vaccinated against shingles are 42% less likely to develop the disease after undergoing chemotherapy. The vaccine also prevented hospitalizations for shingles among vaccinated patients, highlighting its importance in preventing long-term complications.
Researchers tested genetically engineered virus alongside isolated limb perfusion chemotherapy, finding it more effective in rats than either treatment alone. The combination slowed tumour growth and prolonged survival by 50%, offering hope for avoiding amputation and improving quality of life.
Increased use of less toxic chemotherapy treatments in advanced NSCLC is associated with higher overall survival. The study found a significant increase in survival rates among patients receiving second-line therapy, with median overall survival ranging from 3.9 to 11.8 months.
Researchers at IDIBELL and ICO have tested a new therapeutic combination of conventional chemotherapy and rapamycin to combat resistant sarcomas. The Phase I trial showed promising results, with the tumor stopping growth and not recovering after treatment, and has launched a Phase II clinical trial.
Researchers at the University of Georgia have developed a new formulation of cisplatin that significantly increases its ability to target and destroy cancerous cells. The modified version of cisplatin, called Platin-M, is designed to overcome resistance by attacking mitochondria within cancerous cells.
A new study reveals that adipose-derived human stem cells can withstand high doses of the chemotherapy drug methotrexate, unlike other cell types. This finding has significant implications for developing an ASC-based therapy to promote bone growth and regeneration in cancer patients.
A novel intravaginal ring demonstrated controlled drug release and safety in pig-tailed macaque monkeys, showing potential for HIV prevention. The ring's topical delivery reduces adherence issues, boosting effectiveness and minimizing side effects.
A new bone marrow transplantation method has shown promising results in treating adults with severe sickle cell disease, achieving long-term stable donor engraftment and improved hemoglobin levels. The study's findings suggest that this procedure can be applied to older adults with fewer toxic effects.
A large-scale search of a national medical database found that St. John's wort is often prescribed with medications that may result in adverse reactions, such as serotonin syndrome or heart disease. The study highlights the importance of caution when combining St. John's wort with other medications.
Adding cetuximab or bevacizumab to combination chemotherapy improves survival for patients with KRAS wild-type untreated colorectal cancer, with both treatments offering approximately 30-month overall survival. Genetic testing is crucial to determine the benefit of these treatments.
Researchers have discovered a potential treatment for tuberculosis (TB) by targeting the body's immune response rather than directly killing the bacteria. This new host-directed therapy has shown promise in preventing disease severity and controlling bacterial growth, offering hope for those infected with drug-resistant strains.
Saint Louis University researchers have discovered a molecular pathway that causes painful chemotherapy side effects and found a potential way to block it. A drug already approved for treating multiple sclerosis may also alleviate chemotherapy-induced peripheral neuropathy (CIPN) without affecting the medication's anticancer properties.
Researchers developed a hydrogel that releases chemotherapy drugs in short bursts triggered by ultrasound, improving cancer treatment outcomes. The self-healing gel approach offers a more effective and minimally invasive method for delivering drugs at the right place and time.
A new drug called selumetinib has been found to delay progression of metastatic uveal melanoma, increasing progression-free survival by over double that of chemotherapy. The study's findings demonstrate a potential treatment approach for this rare and deadly form of melanoma.
A study found that selumetinib improved cancer progression-free survival time and tumor response rate in patients with advanced uveal melanoma, but had no impact on overall survival. Treatment-related adverse events were common, affecting nearly all patients.
Scientists have identified a new biomarker called Neuromedin U (NmU) that may help predict and overcome resistance to newer anti-cancer drugs for HER2 positive cancers. The discovery could lead to more effective treatment strategies and improved patient outcomes.
Scientists at EPFL introduce a novel biosensor molecule that can quickly measure drug concentration in patients' systems using a digital camera. The method is simple, low-cost, and can be used by patients themselves.
Researchers found that fasting can replenish stem cells in the blood, combating chemotherapy-induced and aging-related changes in immune cell function. Fasting has also been shown to rejuvenate the immune system of old mice and protect against white blood cell loss in human patients.
A Kaiser Permanente study published in the Journal of Clinical Oncology found that patients with small HER2+ breast cancer tumors (<0.5 cm) had a high survival rate without distant recurrence, even without treatment. For larger tumors (0.6-1 cm), the risk was slightly lower but still remained low.